Genetic Analysis AS (GEAN): Notice of Extraordinary General Meeting
OSLO, NORWAY – 13 September 2021: Notice is hereby served of an extraordinary general meeting of Genetic Analysis AS (the “Company”). The general meeting will be held in the Company’s…
The subscription period begins in Genetic Analysis AS issue of units prior to planned listing on Spotlight Stock Market
OSLO, NORWAY – 30 August 2021: Today, the subscription period begins in Genetic Analysis (“GA” or “the Company”) issue of units (“the IPO”) prior to the planned listing on Spotlight…
Genetic Analysis AS receives preliminary approval for listing and publishes prospectus in connection with planned IPO
OSLO, NORWAY – 24 August 2021: Genetic Analysis AS (“GA” or “the Company”) hereby announces that the Company has received preliminary approval for listing on Spotlight Stock Market (“Spotlight”). The…
Genetic Analysis AS releases Interim report January – June 2021
(Oslo, 20 August 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – June 30, 2021. The interim report is available…
Genetic Analysis Co-develops HumGut – The world’s first complete database of reference genomes
Molecular diagnostics specialist, Genetic Analysis AS (GA) todayannounced the first publication from the comprehensive HumGut microbiome database hasappeared in the leading scientific journal Microbiome. HumGut comprises a collection ofabout 30,000…
Eagle Biosciences Announces Agreement with Genetic Analysis AS for Distribution in North America
“North America is for sure going to accelerate the growth in the human microbiome market moving forward. We at GA are very excited to fuel this growth with our GA-map®…
Genetic Analysis awarded NOK 16 million to develop microbiome marker to aid treatment of Inflammatory Bowel Disease
In this project, GA will develop an easy to use, in vitro diagnostic test that profiles gutmicrobiota to predict disease progression and treatment regimes in patients with ulcerativecolitis. The development…
Genetic Analysis Joins Microbiome Therapeutics Innovation Group
The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Norwegian molecular diagnostic company Genetic Analysis AS to its coalition of companies leading the research and development of FDA-approved…
Genetic Analysis AS announces that a patent was granted in the US, from family WO2016120494A
“METHOD AND PRODUCT FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S”. In March 2019, GA signed a license agreement with the university NMBU’ Tech transfer office that secured GA global…
Genetic Analysis AS announces that a patent was granted in India, from family WO2012080754A2
“OLIGONUCLEOTIDE PROBE SET AND METHODS OF MICROBIOTA PROFILING”. We are very pleased to inform that our patent “Oligonucleotide probe set and methods of microbiota profiling” has been granted in India…
Genetic Analysis AS announces that two patents were granted in Russia and EU, from family WO2016156251A1
“METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS”. New IP secured – Important patents enhancing the use of GA-map® granted in EU and Russia. The object of this family of patents relates…
Successful share issue and change in the management team
Successful share issue Genetic Analysis AS announces the successful private placement of NOK 34.3 million. The issue was oversubscribed and completed in two tranches; the first tranche closed on June 19th was aimed at…